On Wednesday, GSK announced positive results from a Phase III clinical trial for its new oral antibiotic against gonorrhea, a sexually transmitted infection that is increasingly resistant to existing treatments.

The trial, says the British laboratory in a press release, showed that at a medical visit three to seven days after treatment, its gepotidacin was more effective (92.6%) than the current standard treatment, based on the combination of intramuscular ceftriaxone and oral azithromycin (91.2%).

According to GSK, there are some 82 million new cases of gonorrhea every year, including 648,056 in the United States, equivalent to a 118% jump between 2009 and 2021 according to the CDC.

According to the CDC, half of all cases of gonorrhea are now resistant to at least one antibiotic treatment.

Copyright (c) 2024 CercleFinance.com. All rights reserved.